Servier Strikes USD 2.5 Billion Deal to Buy Day One Biopharmaceuticals
French drugmaker Servier has agreed to acquire US-based Day One Biopharmaceuticals in an all-cash deal valued at approximately USD 2.5 billion, as the company seeks to strengthen its presence in rare oncology and brain tumour therapies.
One Biopharmaceuticals | 07/03/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy